Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

MDH1 deficiency is a metabolic disorder of the malate-aspartate shuttle associated with early onset severe encephalopathy.

Broeks MH, Shamseldin HE, Alhashem A, Hashem M, Abdulwahab F, Alshedi T, Alobaid I, Zwartkruis F, Westland D, Fuchs S, Verhoeven-Duif NM, Jans JJM, Alkuraya FS.

Hum Genet. 2019 Sep 19. doi: 10.1007/s00439-019-02063-z. [Epub ahead of print]

PMID:
31538237
2.

A Green Water-Soluble Cyclophosphazene as a Flame Retardant Finish for Textiles.

Mayer-Gall T, Plohl D, Derksen L, Lauer D, Neldner P, Ali W, Fuchs S, Gutmann JS, Opwis K.

Molecules. 2019 Aug 26;24(17). pii: E3100. doi: 10.3390/molecules24173100.

3.

Short-term hypoxia promotes vascularization in co-culture system consisting of primary human osteoblasts and outgrowth endothelial cells.

Ma B, Li M, Fuchs S, Bischoff I, Hofmann A, Unger RE, Kirkpatrick CJ.

J Biomed Mater Res A. 2019 Aug 20. doi: 10.1002/jbm.a.36786. [Epub ahead of print]

PMID:
31430039
4.

Evaluation of bone allograft processing methods: Impact on decellularization efficacy, biocompatibility and mesenchymal stem cell functionality.

Rasch A, Naujokat H, Wang F, Seekamp A, Fuchs S, Klüter T.

PLoS One. 2019 Jun 20;14(6):e0218404. doi: 10.1371/journal.pone.0218404. eCollection 2019.

5.

Identification of human D lactate dehydrogenase deficiency.

Monroe GR, van Eerde AM, Tessadori F, Duran KJ, Savelberg SMC, van Alfen JC, Terhal PA, van der Crabben SN, Lichtenbelt KD, Fuchs SA, Gerrits J, van Roosmalen MJ, van Gassen KL, van Aalderen M, Koot BG, Oostendorp M, Duran M, Visser G, de Koning TJ, Calì F, Bosco P, Geleijns K, de Sain-van der Velden MGM, Knoers NV, Bakkers J, Verhoeven-Duif NM, van Haaften G, Jans JJ.

Nat Commun. 2019 Apr 1;10(1):1477. doi: 10.1038/s41467-019-09458-6.

6.

Glycogen Storage Disease Type IV: A Rare Cause for Neuromuscular Disorders or Often Missed?

Schene IF, Korenke CG, Huidekoper HH, van der Pol L, Dooijes D, Breur JMPJ, Biskup S, Fuchs SA, Visser G.

JIMD Rep. 2019;45:99-104. doi: 10.1007/8904_2018_148. Epub 2018 Dec 20.

7.

Whole Exome Sequencing Is the Preferred Strategy to Identify the Genetic Defect in Patients With a Probable or Possible Mitochondrial Cause.

Theunissen TEJ, Nguyen M, Kamps R, Hendrickx AT, Sallevelt SCEH, Gottschalk RWH, Calis CM, Stassen APM, de Koning B, Mulder-Den Hartog ENM, Schoonderwoerd K, Fuchs SA, Hilhorst-Hofstee Y, de Visser M, Vanoevelen J, Szklarczyk R, Gerards M, de Coo IFM, Hellebrekers DMEI, Smeets HJM.

Front Genet. 2018 Oct 12;9:400. doi: 10.3389/fgene.2018.00400. eCollection 2018.

8.

Towards incentivising integration: A typology of payments for integrated care.

Stokes J, Struckmann V, Kristensen SR, Fuchs S, van Ginneken E, Tsiachristas A, Rutten van Mölken M, Sutton M.

Health Policy. 2018 Sep;122(9):963-969. doi: 10.1016/j.healthpol.2018.07.003. Epub 2018 Jul 11. Review.

9.

Aminoacyl-tRNA synthetase deficiencies in search of common themes.

Fuchs SA, Schene IF, Kok G, Jansen JM, Nikkels PGJ, van Gassen KLI, Terheggen-Lagro SWJ, van der Crabben SN, Hoeks SE, Niers LEM, Wolf NI, de Vries MC, Koolen DA, Houwen RHJ, Mulder MF, van Hasselt PM.

Genet Med. 2019 Feb;21(2):319-330. doi: 10.1038/s41436-018-0048-y. Epub 2018 Jun 6.

PMID:
29875423
10.

Testing a new taxonomic model for the assessment of medical devices: Is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe.

Fuchs S, Olberg B, Perleth M, Busse R, Panteli D.

Health Policy. 2019 Feb;123(2):173-181. doi: 10.1016/j.healthpol.2018.03.004. Epub 2018 Mar 14.

PMID:
29703653
11.

Timing of cognitive decline in CLN3 disease.

Kuper WFE, van Alfen C, Rigterink RH, Fuchs SA, van Genderen MM, van Hasselt PM.

J Inherit Metab Dis. 2018 Mar;41(2):257-261. doi: 10.1007/s10545-018-0143-x. Epub 2018 Feb 1.

12.

Scientific Evidence in Health Technology Assessment Reports: An In-Depth Analysis of European Assessments on High-Risk Medical Devices.

Olberg B, Fuchs S, Panteli D, Perleth M, Busse R.

Value Health. 2017 Dec;20(10):1420-1426. doi: 10.1016/j.jval.2017.05.011. Epub 2017 Jun 20. Review.

13.

Site-specific and endothelial-mediated dysfunction of the alveolar-capillary barrier in response to lipopolysaccharides.

Janga H, Cassidy L, Wang F, Spengler D, Oestern-Fitschen S, Krause MF, Seekamp A, Tholey A, Fuchs S.

J Cell Mol Med. 2018 Feb;22(2):982-998. doi: 10.1111/jcmm.13421. Epub 2017 Dec 5.

14.

Evidence-based decision-making for diagnostic and therapeutic methods: the changing landscape of assessment approaches in Germany.

Olberg B, Fuchs S, Matthias K, Nolting A, Perleth M, Busse R.

Health Res Policy Syst. 2017 Oct 17;15(1):89. doi: 10.1186/s12961-017-0253-1.

15.

Novel therapeutic roles for surfactant-inositols and -phosphatidylglycerols in a neonatal piglet ARDS model: a translational study.

Spengler D, Winoto-Morbach S, Kupsch S, Vock C, Blöchle K, Frank S, Rintz N, Diekötter M, Janga H, Weckmann M, Fuchs S, Schromm AB, Fehrenbach H, Schütze S, Krause MF.

Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L32-L53. doi: 10.1152/ajplung.00128.2017. Epub 2017 Aug 31.

16.

Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines.

Dithmer M, Kirsch AM, Richert E, Fuchs S, Wang F, Schmidt H, Coupland SE, Roider J, Klettner A.

Mar Drugs. 2017 Jun 22;15(7). pii: E193. doi: 10.3390/md15070193.

17.

Crude Fucoidan Extracts Impair Angiogenesis in Models Relevant for Bone Regeneration and Osteosarcoma via Reduction of VEGF and SDF-1.

Wang F, Schmidt H, Pavleska D, Wermann T, Seekamp A, Fuchs S.

Mar Drugs. 2017 Jun 20;15(6). pii: E186. doi: 10.3390/md15060186.

18.

Hepatocytes express the antimicrobial peptide HBD-2 after multiple trauma: an experimental study in human and mice.

Fitschen-Oestern S, Weuster M, Lippross S, Behrendt P, Fuchs S, Pufe T, Tohidnezhad M, Bayer A, Seekamp A, Varoga D, Klüter T.

BMC Musculoskelet Disord. 2017 Mar 7;18(1):100. doi: 10.1186/s12891-017-1458-8.

19.

Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy.

Ait-El-Mkadem S, Dayem-Quere M, Gusic M, Chaussenot A, Bannwarth S, François B, Genin EC, Fragaki K, Volker-Touw CLM, Vasnier C, Serre V, van Gassen KLI, Lespinasse F, Richter S, Eisenhofer G, Rouzier C, Mochel F, De Saint-Martin A, Abi Warde MT, de Sain-van der Velde MGM, Jans JJM, Amiel J, Avsec Z, Mertes C, Haack TB, Strom T, Meitinger T, Bonnen PE, Taylor RW, Gagneur J, van Hasselt PM, Rötig A, Delahodde A, Prokisch H, Fuchs SA, Paquis-Flucklinger V.

Am J Hum Genet. 2017 Jan 5;100(1):151-159. doi: 10.1016/j.ajhg.2016.11.014. Epub 2016 Dec 15.

20.

HTA of medical devices: Challenges and ideas for the future from a European perspective.

Fuchs S, Olberg B, Panteli D, Perleth M, Busse R.

Health Policy. 2017 Mar;121(3):215-229. doi: 10.1016/j.healthpol.2016.08.010. Epub 2016 Sep 14.

PMID:
27751533

Supplemental Content

Loading ...
Support Center